Curis Hedgehog and Beyond --plus multi-targeting cancer inhibitors

Novel Anti-Cancer therapies

Skip to content

Infinity Pharmaceuticals hedgehog inhibitor IPI-926

List of Clinical Hedgehog Pathway Cancers
Post a reply

Infinity Pharmaceuticals hedgehog inhibitor IPI-926

Postby hedgehog » Mon Feb 08, 2010 6:56 pm

Advanced and/or Metastatic Solid Tumor Malignancies PI
http://clinicaltrials.gov/ct2/show/NCT00761696?term=IPI-926
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

http://clinicaltrials.gov/ct2/results?term=IPI-926
hedgehog
Site Admin
 
Posts: 28
Joined: Sun Feb 07, 2010 8:53 pm
Top

Re: Infinity Pharmaceuticals hedgehog inhibitor IPI-926

Postby hedgehog » Sat Feb 27, 2010 5:06 pm

Product Candidate: IPI-926

    IPI-926 is a novel, potent, orally-available small molecule inhibitor of the Hedgehog pathway. Malignant activation of the Hedgehog pathway is implicated in multiple cancer settings and Infinity's development strategy is designed to enable IPI-926 to target a broad range of critical oncology targets - from the tumor cell to the cancer microenvironment. This broadly applicable, targeted approach represents an innovative method for fighting cancer and has potential in treating a range of cancers, including pancreatic cancer, small cell lung cancer, ovarian cancer, bladder cancer, medulloblastoma, basal cell carcinoma, and certain hematological malignancies.

    Infinity is currently evaluating IPI-926 in a Phase 1 trial in patients with advanced solid tumors. Data from this trial are expected to be presented in 2010, and Infinity anticipates initiating Phase 2 development later this year.

    Infinity has reported preclinical data on IPI926 demonstrating significant anti-tumor activity and excellent pharmaceutical properties, including oral bioavailability, long plasma and tumor half-life, and dose-dependent inhibition of tumor growth. For all scientific publications relating to IPI-926 and the Hedgehog signaling pathway, click here.

    Infinity has an issued U.S. patent broadly covering the composition of matter of a genus of compounds, including IPI-926, useful for modulating the Hedgehog signaling pathway.

Hedgehog Pathway
http://www.infi.com/video4.swf
    The Hedgehog signaling pathway represents a new way of understanding and potentially attacking the progression and reoccurrence of cancer. The Hedgehog pathway is normally active during embryonic development and regulates tissue and organ formation. Malignant activation of the Hedgehog pathway is believed to play a central role in allowing the proliferation and survival of cancer cells, including pancreatic, prostate, small cell lung, breast, and hematologic cancers, as well as certain skin and brain cancers.

How Does Hedgehog Pathway Inhibition Function?
http://www.infi.com/images/MOA-Hedgehog.swf
    Infinity is developing a novel, proprietary Hedgehog pathway inhibitor,
    IPI-926. In preclinical models, IPI-926 has shown potent and selective inhibition of the Hedgehog pathway, anti-tumor activity, and attractive pharmacologic properties, including oral bioavailability and favorable half-life. IPI-926 is currently being evaluated in a Phase 1 clinical trial and is part of Infinity's global strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited.

hedgehog
Site Admin
 
Posts: 28
Joined: Sun Feb 07, 2010 8:53 pm
Top
Post a reply

Return to Hedgehog Pathway Cancers Clinical Trials

Who is online

Users browsing this forum: No registered users and 0 guests

Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group

phpBB SEO
cron